Sector News

Selvita and the University of Oxford join forces to tackle Parkinson’s disease

June 11, 2023
Life sciences

The collaboration centres on developing protein degraders that could provide an additional approach for treating the disease.

The Polish drug discovery and service provider Selvita has announced a new collaboration with the University of Oxford to advance the development of Parkinson’s disease therapies.

Parkinson’s is caused by a build-up of alpha-synuclein, a small protein, forming aggregates inside vulnerable neurons. Cells are then unable to efficiently clear these aggregates, potentially killing neurons and allowing the disease to progress.

The team at Oxford, led by George Tofaris, PhD, Professor of Neurology and Translational Neuroscience at the university, has identified key protein disposal factors that affect alpha-synuclein aggregation. Selvita believes these could be important drug targets for disease modification, preventing its progression further, as per a 5 June press release.

In an email to Pharmaceutical Technology, a Selvita spokesperson stated the company’s plans to build from the team’s research to develop protein degraders. By combining academic knowledge of the disease’s biology from Oxford, and Selvita’s own technical drug discovery capabilities, the company believes the collaboration best positioned them to develop protein degraders.

Parkinson’s disease is the second most common neurodegenerative disease, with roughly seven million people affected worldwide. Despite this, existing treatments are only symptomatic, unable to slow or stop the disease’s progression.

A GlobalData analysis found a lack of disease-modifying therapies (DMTs) for Parkinson’s was one of the highest unmet needs. Any company that could provide DMTs would have ample opportunities for market entry, as they could bring about a major shift in patient treatment.

GlobalData is the parent company of Pharmaceutical Technology.

Across the seven major markets (US, UK, Japan, Germany, France, Spain and Italy) the market for Parkinson’s disease treatment is set to grow significantly over the next few years, from $4.6bn in 2023 to $11.5bn. The US market is driving this growth, forecasted to nearly triple from $2.4bn in 2023 to $7.4bn by 2029, as per GlobalData.

At this stage, the Selvita spokesperson said it would be premature to commit to any development timeline, but added that they were hopeful to see applications go to trial in the future.

By Aidan McNamee

Source: pharmaceutical-technology.com

comments closed

Related News

April 14, 2024

Bayer taps new North America marketing chief for consumer health division

Life sciences

Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble.

April 14, 2024

Air Liquide acquires healthcare businesses in Belgium and the Netherlands

Life sciences

Air Liquide S.A. (Paris) is continuing its development with the acquisition of Homecare activities in Belgium and the Netherlands. The two entities acquired in Belgium and the Netherlands support 10,000 patients living with respiratory insufficiency, sleep apnea syndrome or requiring infusion or nutrition treatments.

April 14, 2024

Vertex to acquire Alpine Immune Sciences for $4.9 billion

Life sciences

US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.

How can we help you?

We're easy to reach